Stifel Nicolaus analyst Annabel Samimy has maintained their bullish stance on APLS stock, giving a Buy rating today. Annabel Samimy’s rating is based on Apellis Pharmaceuticals’ strategic initiatives and growth
Stifel Nicolaus analyst Annabel Samimy has maintained their bullish stance on APLS stock, giving a Buy rating today. Annabel Samimy’s rating is based on Apellis Pharmaceuticals’ strategic initiatives and growth
Stifel lowered the firm’s price target on Apellis (APLS) to $75 from $84 and keeps a Buy rating on the shares. Feeling headwinds from competitive forces, the company reported Q3